Ademetionine (S-adenosylmethionine) neuropharmacology: implications for drug therapies in psychiatric and neurological disorders.
Ademetionine (S-adenosylmethionine; SAMe) is a ubiquitous metabolite present in all cells and biological fluids, and serves as a methyl donor in a multitude of different methylation reactions involving proteins, phospholipids, catecholamines and DNA. Pharmaceutical preparations of some stable salts of SAMe are available for parenteral and oral use in humans, and have been shown to increase plasma and cerebrospinal fluid SAMe concentrations. In experimental studies administration of SAMe is associated with increases in brain monoamine neurotransmitters and b-adrenergic and muscarinic receptor functions. These neuropharmacological effects are postulated to be involved in the antidepressant activity of SAMe which has been confirmed in numerous controlled studies. Preliminary studies indicate that SAMe has therapeutic potential in the treatment of other CNS disorders including dementia, acquired immune deficiency syndrome (AIDS)-associated myelopathy, and brain ischaemia. This review will focus on recent experimental and clinical aspects of SAMe in the central nervous system, and the therapeutic use in psychiatric and neurological disorders.
Bottiglieri
T
T
Kimberly H Courtwright & Joseph W Summers Institute of Metabolic Disease, Baylor University Medical Center, 3812 Elm Street, Dallas, Texas 75226, USA. t.bottiglieri@baylordallas.edu